Tisdag 26 November | 04:56:21 Europe / Stockholm
Svenska | English

Bio-Works Technologies

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-21 08:30 Bokslutskommuniké 2024
2024-08-02 - Kvartalsrapport 2024-Q2
2024-07-29 - Extra Bolagsstämma 2024
2024-05-27 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2024-05-24 - Årsstämma
2024-02-19 - Bokslutskommuniké 2023
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-29 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2023-05-26 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-23 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-05-20 - Årsstämma
2022-05-06 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-02-18 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-24 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 - Årsstämma
2021-02-19 - Bokslutskommuniké 2020
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-18 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 - Årsstämma
2020-02-14 - Bokslutskommuniké 2019
2019-10-18 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-27 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 - Årsstämma
2019-04-29 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-08-19 - Kvartalsrapport 2018-Q2
2018-05-21 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 - Årsstämma
2018-02-19 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Bio-Works Technologies är verksamt inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.
Bio-Works receives an additional order worth SEK 2.9 million for WorkBeads
2024-05-07 16:11:00

Bio-Works has received another order from a production customer in the Netherlands who placed two orders earlier this year. The latest order is worth SEK 2.9 million. The customer is a global manufacturer of active pharmaceutical ingredients (API) with approximately 1,800 employees.

"This is further evidence that Bio-Works’ production customers value our products and customer service very highly," said Jonathan Royce, CEO of Bio-Works. "Our continuous efforts to expand business with existing customers who have already approved Bio-Works as a supplier are bearing fruit. At the same time, we are working hard to acquire new customers in order to broaden our customer base for the future.”

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB is appointed Certified Adviser. For more information, visit www.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-07 16:11 CEST.

Attachments
Bio-Works receives an additional order worth SEK 2.9 million for WorkBeads

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden